| Literature DB >> 27836958 |
Jane S Lucas1,2, Angelo Barbato3, Samuel A Collins4,2, Myrofora Goutaki5,6, Laura Behan4,2, Daan Caudri7,8, Sharon Dell9,10, Ernst Eber11, Estelle Escudier12,13, Robert A Hirst14, Claire Hogg15, Mark Jorissen16, Philipp Latzin6, Marie Legendre12,13, Margaret W Leigh17, Fabio Midulla18, Kim G Nielsen19, Heymut Omran20, Jean-Francois Papon21,22, Petr Pohunek23, Beatrice Redfern24, David Rigau25, Bernhard Rindlisbacher26, Francesca Santamaria27, Amelia Shoemark15, Deborah Snijders3, Thomy Tonia5, Andrea Titieni20, Woolf T Walker4,2, Claudius Werner20, Andrew Bush15, Claudia E Kuehni5.
Abstract
The diagnosis of primary ciliary dyskinesia is often confirmed with standard, albeit complex and expensive, tests. In many cases, however, the diagnosis remains difficult despite the array of sophisticated diagnostic tests. There is no "gold standard" reference test. Hence, a Task Force supported by the European Respiratory Society has developed this guideline to provide evidence-based recommendations on diagnostic testing, especially in light of new developments in such tests, and the need for robust diagnoses of patients who might enter randomised controlled trials of treatments. The guideline is based on pre-defined questions relevant for clinical care, a systematic review of the literature, and assessment of the evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. It focuses on clinical presentation, nasal nitric oxide, analysis of ciliary beat frequency and pattern by high-speed video-microscopy analysis, transmission electron microscopy, genotyping and immunofluorescence. It then used a modified Delphi survey to develop an algorithm for the use of diagnostic tests to definitively confirm and exclude the diagnosis of primary ciliary dyskinesia; and to provide advice when the diagnosis was not conclusive. Finally, this guideline proposes a set of quality criteria for future research on the validity of diagnostic methods for primary ciliary dyskinesia.Entities:
Mesh:
Substances:
Year: 2017 PMID: 27836958 PMCID: PMC6054534 DOI: 10.1183/13993003.01090-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671